The ‘Holy Grail’ in Immuno-Oncology: AC BioScience SA is Aiming to Potentiate Anti-PD-1 Therapy Efficacy through Tumor Cell Conditioning Strategy

Andreas Schläpfer; Christian Auclair; Bassam Janji; Manale Karam; Muhammad Zaeem Noman

doi:10.2533/CHIMIA.2020.771

The ‘Holy Grail’ in Immuno-Oncology: AC BioScience SA is Aiming to Potentiate Anti-PD-1 Therapy Efficacy through Tumor Cell Conditioning Strategy

Andreas Schläpfer^*, Christian Auclair, Bassam Janji, Manale Karam, Muhammad Zaeem Noman

^*Corresponding author for this work

Tumor Immunotherapy and Microenvironment

Research output: Contribution to journal › Article › Research › peer-review

1 Citation (Scopus)

Abstract

AC BioScience is a Swiss biotech company based at the EPFL Innovation Park and Biopôle, dedicated to developing groundbreaking therapies to fight a range of cancers and infectious diseases. We are about to start clinical trials with two of four leading-edge cancer drugs mainly focusing on immune-oncology and tumor vascular normalization with multi-billion $ sales potential. Here, we present our strategy and one of our pioneering drug candidates that has already shown exceptional results with tumor cell conditioning to improve the efficacy of immune checkpoint inhibitors.

Original language	English
Pages (from-to)	771-775
Number of pages	5
Journal	Chimia
Volume	74
Issue number	10
DOIs	https://doi.org/10.2533/CHIMIA.2020.771
Publication status	Published - Oct 2020

Keywords

AC Bioscience SA
ACB1801
Cancer therapies
Immune checkpoint inhibitors
Swiss biotech

Access to Document

10.2533/CHIMIA.2020.771

Cite this

@article{91ea51bf6faa4ba7b36abda36f5550e6,

title = "The {\textquoteleft}Holy Grail{\textquoteright} in Immuno-Oncology: AC BioScience SA is Aiming to Potentiate Anti-PD-1 Therapy Efficacy through Tumor Cell Conditioning Strategy",

abstract = "AC BioScience is a Swiss biotech company based at the EPFL Innovation Park and Biop{\^o}le, dedicated to developing groundbreaking therapies to fight a range of cancers and infectious diseases. We are about to start clinical trials with two of four leading-edge cancer drugs mainly focusing on immune-oncology and tumor vascular normalization with multi-billion $ sales potential. Here, we present our strategy and one of our pioneering drug candidates that has already shown exceptional results with tumor cell conditioning to improve the efficacy of immune checkpoint inhibitors.",

keywords = "AC Bioscience SA, ACB1801, Cancer therapies, Immune checkpoint inhibitors, Swiss biotech",

author = "Andreas Schl{\"a}pfer and Christian Auclair and Bassam Janji and Manale Karam and Noman, {Muhammad Zaeem}",

note = "Publisher Copyright: {\textcopyright} A. Schl{\"a}pfer, C. Auclair, B. Janji, M. Karam, M. Zaeem Noman",

year = "2020",

month = oct,

doi = "10.2533/CHIMIA.2020.771",

language = "English",

volume = "74",

pages = "771--775",

journal = "Chimia",

issn = "0009-4293",

publisher = "Swiss Chemical Society",

number = "10",

}

TY - JOUR

T1 - The ‘Holy Grail’ in Immuno-Oncology

T2 - AC BioScience SA is Aiming to Potentiate Anti-PD-1 Therapy Efficacy through Tumor Cell Conditioning Strategy

AU - Schläpfer, Andreas

AU - Auclair, Christian

AU - Janji, Bassam

AU - Karam, Manale

AU - Noman, Muhammad Zaeem

N1 - Publisher Copyright: © A. Schläpfer, C. Auclair, B. Janji, M. Karam, M. Zaeem Noman

PY - 2020/10

Y1 - 2020/10

N2 - AC BioScience is a Swiss biotech company based at the EPFL Innovation Park and Biopôle, dedicated to developing groundbreaking therapies to fight a range of cancers and infectious diseases. We are about to start clinical trials with two of four leading-edge cancer drugs mainly focusing on immune-oncology and tumor vascular normalization with multi-billion $ sales potential. Here, we present our strategy and one of our pioneering drug candidates that has already shown exceptional results with tumor cell conditioning to improve the efficacy of immune checkpoint inhibitors.

AB - AC BioScience is a Swiss biotech company based at the EPFL Innovation Park and Biopôle, dedicated to developing groundbreaking therapies to fight a range of cancers and infectious diseases. We are about to start clinical trials with two of four leading-edge cancer drugs mainly focusing on immune-oncology and tumor vascular normalization with multi-billion $ sales potential. Here, we present our strategy and one of our pioneering drug candidates that has already shown exceptional results with tumor cell conditioning to improve the efficacy of immune checkpoint inhibitors.

KW - AC Bioscience SA

KW - ACB1801

KW - Cancer therapies

KW - Immune checkpoint inhibitors

KW - Swiss biotech

UR - http://www.scopus.com/inward/record.url?scp=85094867363&partnerID=8YFLogxK

U2 - 10.2533/CHIMIA.2020.771

DO - 10.2533/CHIMIA.2020.771

M3 - Article

C2 - 33115558

AN - SCOPUS:85094867363

SN - 0009-4293

VL - 74

SP - 771

EP - 775

JO - Chimia

JF - Chimia

IS - 10

ER -

The ‘Holy Grail’ in Immuno-Oncology: AC BioScience SA is Aiming to Potentiate Anti-PD-1 Therapy Efficacy through Tumor Cell Conditioning Strategy

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this